Information Provided By: 
Fly News Breaks for April 24, 2018
JUNO, CLLS, EPZM
Apr 24, 2018 | 08:43 EDT
Jefferies analyst Michael Yee says that while the partial clinical hold is a bad headline, shares of Epizyme (EPZM) will bounce back like Cellectis (CLLS), Juno and others did when they modified the protocol and trial brochures to get back up and running. After speaking to management, Yee thinks Epizyme's partial clinical hold will be lifted in a few months. Until then, however, the shares could be in the penalty box, the analyst tells investors in a research note. He keeps a Buy rating on Epizyme with a $27 price target.
News For EPZM;CLLS;JUNO From the Last 2 Days
There are no results for your query EPZM;CLLS;JUNO
